Kerins Patrick J's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jan 14, 2022
- Accession no.
- 0001209191-22-003357
- Filed
- Jan 14, 2022, 5:04 PM ET
- Trade date
- Jan 12-14, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $41.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kerins Patrick JCIK 0001235112 | 10% Owner |
| Sandell Scott DCIK 0001237289 | 10% Owner |
| Baskett ForestCIK 0001277631 | 10% Owner |
| New Enterprise Associates 14, L.P.CIK 0001544328 | 10% Owner |
| NEA Partners 14, L.P.CIK 0001551531 | 10% Owner |
| Nea 14 GP, LtdCIK 0001551532 | 10% Owner |
| Sonsini Peter W.CIK 0001559807 | 10% Owner |
| Florence Anthony A. Jr.CIK 0001559827 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2022 | Common Stock | SSaleDisposed | −4,634 | $2.02 | −$9,357.44 | 3,483,630 | Direct | |
| Jan 13, 2022 | Common Stock | SSaleDisposed | −7,209 | $1.93 | −$13,885.98 | 3,476,421 | Direct | |
| Jan 14, 2022 | Common Stock | SSaleDisposed | −9,707 | $1.91 | −$18,583.08 | 3,466,714 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.